Equities

Angelalign Technology Inc

Angelalign Technology Inc

Actions
Health CareMedical Equipment and Services
  • Price (HKD)52.90
  • Today's Change1.20 / 2.32%
  • Shares traded125.60k
  • 1 Year change-25.86%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ANGELALIGN TECHNOLOGY Inc is a clear aligner dental treatment solution provider. The Company provides dental professionals with self-developed digital orthodontics solutions. The Company’s Angelalign clear aligner system facilitate dental professionals throughout the entire clear aligner treatment process, include digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, help dental professionals design, review and modify treatment plans; customized, removable clear aligners based on specific treatment plans, is a removable, transparent, plastic form of dental braces used to treat malocclusion; and cloud-based service platform, iOrtho, helps to placing orders, reviewing, modifying and finalizing their treatment plans online with the help from its medical designers, and reviewing, editing and managing medical records of their patients.

  • Revenue in HKD (TTM)1.59bn
  • Net income in HKD57.73m
  • Incorporated2018
  • Employees2.88k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Microport NeuroTech Ltd-100.00bn-100.00bn4.56bn571.00------------------------------------------------21.61--768.73------
Shanghai Conant Optical Co Ltd1.90bn353.04m4.78bn2.51k13.533.1711.502.520.82760.82764.453.530.93282.166.48757,139.4017.3412.5722.4018.6937.4035.2718.5814.642.15--0.133518.5712.7015.5631.5633.0413.49--
Shanghai INT Medical Instruments Co Ltd812.74m168.91m4.89bn1.57k28.232.6622.576.020.98470.98474.7410.470.39042.227.75518,661.307.958.639.499.7658.1959.4420.3526.161.88--0.053531.8028.5029.9618.7921.7645.75--
AK Medical Holdings Ltd1.18bn196.59m4.96bn1.05k25.171.9216.834.200.17560.17561.062.300.37870.84062.381,122,533.006.309.277.5211.2861.6665.0616.6521.782.77--0.043122.653.9712.74-11.074.6721.675.88
Lepu Scientch Mdcl Tchnlgy Shnghi Co Ltd351.83m163.59m6.21bn219.0037.942.9834.5117.640.47180.47181.016.000.17170.584810.301,606,525.007.98--8.25--88.62--46.50--22.93--0.0013--31.58--864.81------
LifeTech Scientific Corp1.37bn284.19m6.44bn1.45k21.931.7733.874.700.06340.06340.30770.78580.30220.749110.46946,064.502.567.093.058.5178.5779.668.4822.692.27--0.14590.0015.4817.88-19.0916.8026.11--
New Horizon Health Ltd1.47bn119.43m6.47bn1.04k59.172.0141.624.400.2390.2393.227.040.45362.162.081,674,671.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
Shanghai MicroPort MedBot Group Co Ltd112.91m-1.09bn6.62bn650.00--11.64--58.59-1.14-1.140.11780.5850.06230.374642.10173,715.10-60.96---86.19--14.05---978.59--0.8238-11.040.5427--384.16--11.20------
Kangji Medical Holdings Ltd999.71m544.13m6.79bn1.00k12.051.7312.966.790.4640.4640.85253.240.22451.764.76996,720.3010.9714.4012.4516.1880.0481.7548.8457.2417.16--0.01149.5817.7621.235.2828.0041.50--
Angelalign Technology Inc1.59bn57.73m8.95bn2.88k154.642.4861.945.620.34210.34219.4421.330.31945.3316.70552,692.101.055.761.297.5962.3864.333.3013.984.12--0.0188--16.2424.75-74.99-2.2020.54--
MicroPort Scientific Corp7.42bn-3.73bn9.65bn8.23k--1.63--1.30-2.04-2.044.073.220.23991.095.32901,790.90-16.38-11.85-27.68-18.0455.9762.96-68.28-44.431.26-4.210.5477--13.077.27-9.42--19.44--
Data as of Jul 26 2024. Currency figures normalised to Angelalign Technology Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

14.31%Per cent of shares held by top holders
HolderShares% Held
Aegon-Industrial Fund Management Co., Ltd.as of 14 Jun 20238.47m5.01%
Capital Research & Management Co. (World Investors)as of 30 Jun 20245.69m3.36%
E Fund Management Co., Ltd.as of 31 Dec 20232.29m1.36%
The Vanguard Group, Inc.as of 04 Jul 20241.72m1.02%
Norges Bank Investment Managementas of 31 Dec 20231.52m0.90%
GF Fund Management Co., Ltd.as of 31 Dec 20231.33m0.78%
Penghua Fund Management Co., Ltd.as of 31 Dec 20231.13m0.67%
Fidelity Management & Research Co. LLCas of 31 May 2024796.20k0.47%
China Asset Management Co., Ltd.as of 31 Dec 2023664.00k0.39%
China Southern Asset Management Co., Ltd.as of 31 Dec 2023602.40k0.36%
More ▼
Data from 31 Dec 2023 - 27 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.